Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment
Key Highlights
- ➤31 participants evaluated Tome Foundational Treatment in a four-week open-label cosmetic study
- ➤93% of participants found Tome comparable to a professional in-office procedure
- ➤90% of participants reported more noticeable results than with other products
- ➤No treatment-related adverse events were reported during the study
- ➤Tome Foundational Treatment is available through one-time purchase or discounted subscription
Expert Statements
Gerry Proehl, Chairman, President, and Chief Executive Officer of Dermata Therapeutics
“We are extremely encouraged by these topline results, which provide clinical support for what we set out to accomplish with Tome, to create a fundamentally different approach to skincare”
Gerry Proehl, Chairman, President, and Chief Executive Officer of Dermata Therapeutics
“Dermata was founded on clinical rigor, and we believe these data help provide the backing for our claim that Tome is ‘studied skincare’”
Gerry Proehl, Chairman, President, and Chief Executive Officer of Dermata Therapeutics
“We believe these topline results demonstrate the potential that a once-weekly skin treatment can visibly renew the appearance of the skin and provide compelling clinical validation at an important time as we introduce Tome to consumers”
Gerry Proehl, Chairman, President, and Chief Executive Officer of Dermata Therapeutics
“We are encouraged by the reception we have seen from the recent launch of Tome Foundational Treatment and look forward to expanding its recognition in the skincare space”
Gerry Proehl, Chairman, President, and Chief Executive Officer of Dermata Therapeutics
“We continue to build awareness around the Tome brand, and believe these clinically demonstrated results, combined with the simplicity of a once-weekly routine, can provide meaningful differentiation for Tome Foundational Treatment in the premium skincare market”
SAN DIEGO, CA / ACCESS Newswire / October 15, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced positive topline results from its recently completed cosmetic clinical study evaluating Tome Foundational Treatment, the Company's recently launched once-weekly skin renewal treatment. Tome Foundational Treatment is now available for purchase at www.tomeskincare.com either as a one-time purchase of four weekly treatments or through a subscription program at a discounted price.
Dermata's recently completed cosmetic clinical study consisted of 31 participants in an open label study of Tome Foundational Treatment. Participants applied Tome Foundational Treatment one time per week for four weeks and were evaluated by an investigator at multiple timepoints throughout the study on endpoints including fine lines, hyperpigmentation, dark spots, smoothness, firmness, radiance, and overall appearance. Participants also completed self-evaluations after four treatments.
Get started
Create a free account to read the full story.